A two-stage decision analysis to assess the cost of 5-aminosalicylic acid failure and the economics of balsalazide versus mesalamine in the treatment of ulcerative colitis

Managed Care Interface

Volumn 19, Issue 10, 2006, Pages

  Mackowiak, John I ^a  

^a Center for Outcomes Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BALSALAZIDE; MESALAZINE; PREDNISONE; STEROID;

ARTICLE; COLON SURGERY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST OF ILLNESS; DRUG CAPSULE; DRUG COST; DRUG FORMULATION; DRUG TREATMENT FAILURE; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HUMAN; MEDICAL DECISION MAKING; MORBIDITY; PATIENT PARTICIPATION; PRACTICE GUIDELINE; PRESCRIPTION; PROCESS MODEL; REMISSION; SYMPTOM; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; DECISION SUPPORT TECHNIQUES; HUMANS; MESALAMINE; PHENYLHYDRAZINES; TREATMENT FAILURE; UNITED STATES;

EID: 33750399472     PISSN: 10965645     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Kornbluth A, Sachar DB: American College of Gastroenterology Practice Parameters Committee. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004;99:1371-1385.
2. Enthoven AC: Shattuck Lecture-cutting cost without cutting the quality of care. N Engl J Med 1978;298:1229-1238.
3. Hay JW, Hay AR: Inflammatory bowel disease: Costs-of-illness. J Clin Gastroenterol 1992;14:309-317.
4. Hay JW, Hay AR: Inflammatory bowel disease: Medical cost algorithms. J Clin Gastroenterol 1992;14:318-327.
5. Hanauer SB, Cohen RD, Becker RV III, et al: Advances in the management of Crohn's disease: Economic and clinical potential of infliximab. Clin Ther 1998;20:1009-1028.
6. Farmer RG, Easley KA, Rankin GB: Clinical patterns, natural history, and progression of ulcerative colitis. A long-term follow-up of 1,116 patients. Dig Dis Sci 1993;38:1137-1146.
7. Swenson BR, Hollenbeak CS, Poritz LS, et al: Modified two-stage ileal pouch-anal anastomosis: Equivalent outcomes with less resource utilization. Dis Colon Rectum 2005;48:256-261.
8. DATA 3.0 User's Manual. Williamstown, MA, Treeage Software Inc., 1997.
9. Cole BF, Glantz MJ, Jaeckle JA, et al: Quality-of-life-adjusted survival comparison of sustained-release cytosine arabinoside versus intrathecal methotrexate for treatment of solid tumor neoplastic meningitis. Cancer 2003;97:3053-3060.
10. Bello CE, Garrett SD: Therapeutic issues in oral glucocorticoid use. Lippincotts Prim Care Pract 1999;3:333-341.
11. Physician Drug & Diagnosis Audit, Yardley, PA, Verispan. 2004.
12. Green JR, Lobo AJ, Holdsworth CD, et al: Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. Gastroenterology 1998;114:15-22.
13. Schroeder KW, Tremaine WJ, Ilstrup DM: Coated oral 5-aminosalcylic acid therapy for mildly to moderately active ulcerative colitis: A randomized study. N Engl J Med 1987;317:1625-1629.
14. Hanauer SB, Sandborn WJ, Kornbluth A, et al: Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: The ASCEND II trial. Am J Gastroenterol 2005;100:2478-2485.
15. Pruitt R, Hanson J, Safdi M, et al: Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. Am J Gastroenterol 2002;97:3078-3086.
16. Levine DS, Riff DS, Pruitt R, et al: A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. Am J Gastroenterol 2002;97:1398-1407.
17. Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al: The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study. Gastroenterology 2001;121:255-260.
18. Levin B: Risk of cancer in ulcerative colitis. Gastrointest Endosc 1999;49:S60-62.
19. Hanauer SB: Medical therapy for ulcerative colitis 2004. Gastroenterology 2004;126:1582-1592.
20. Kirk AP, Lennard-Jones JE: Controlled trial of azathioprine in chronic ulcerative colitis. Br Med J 1982;284:1291-1292.
21. Hawthorne AB, Logan RF, Hawkey CJ, et al: Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 1992;305:20-22.
22. Carbonnel F, Gargouri D, Lemann M, et al: Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis. Aliment Pharmacol Ther 2000;14:273-279.
23. Lindgren SC, Flood LM, Kilander AF, et al: Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol 1998;10:831-835.
24. Lichtiger S, Present DH, Kornbluth A, et al: Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841-1845.
25. D'Haens G, Lemmens L, Geboes K, et al: Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001;120:1323-1329.
26. Carbonnel F, Boruchowicz A, Duclos B, et al: Intravenous cyclosporine in attacks of ulcerative colitis: Short-term and long-term responses. Dig Dis Sci 1996;41:2471-2476.
27. Message L, Bourreille A, Laharie D, et al: Efficacy of intravenous cyclosporin in moderately severe ulcerative colitis refractory to steroids. Gastroenterol Clin et Bio 2005;29:231-235.
28. Sninsky CA, Cort DH, Shanahan F, et al: Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis: A multicenter study. Ann Intern Med 1991;115:350-355.